Biogen fall 6% despite positive Alzheimer’s drug trial data

Biogen’s diranersen posted encouraging Phase 2 CELIA data, with reductions in tau pathology across all doses and cognitive slowing signals, but it missed the primary endpoint on CDR-SB change at Week 76. Shares fell 6% by Thursday’s close after initially jumping 10%, reflecting a mixed read-through. Management plans to advance the Alzheimer’s program to registrational development, though the non-linear dose response and higher serious adverse events at the top dose remain key concerns.

Analysis

This is a classic “good-enough to keep alive, not good enough to underwrite” biotech readout. The market is likely penalizing BIIB because the data set increases confidence in target engagement but reduces confidence in clean dose selection, and that ambiguity matters more in late-stage Alzheimer’s development than a simple binary efficacy beat. The non-linear response at the lowest dose is especially problematic because it suggests either biology is saturating earlier than expected or higher exposure is adding noise/toxicity without incremental benefit.

Second-order, this keeps BIIB in the Alzheimer’s conversation without yet making it an obvious platform winner. If the company advances diranersen, the commercial implication is less about near-term revenue and more about optionality: a validated tau signal could strengthen the case for combo regimens with anti-amyloid drugs and make BIIB relevant in a market where physicians will eventually want mechanistically distinct add-ons. But that also means any future approval path is likely to be slow, biomarker-heavy, and highly sensitive to how regulators interpret surrogate endpoints versus clinical decline.

The bigger tradeable issue is expectation reset. The stock move looks like the market initially priced in a cleaner proof point, then realized this is still a multi-year development asset with a narrow therapeutic window and unresolved dose optimization. Over the next 2-6 weeks, the path of least resistance is probably choppy-to-down unless management communication at the conference reframes the low-dose result as a meaningful efficacy ceiling rather than an artifact. The upside reversal requires either stronger mechanistic detail or a broader peer read-through that improves confidence in tau as a commercially tractable target.

Key Decisions for Investors

• Short BIIB common or buy puts into the next 2-6 weeks of conference/analyst digestion; thesis is that the market will fade the initial enthusiasm as the non-linear dose-response implies weak pricing power for the asset. Risk: a management-led narrative reset that emphasizes biomarker durability and combo potential.
• Pair trade: long REGN / short BIIB over 1-3 months. REGN has cleaner cash-flow visibility and less binary pipeline risk; BIIB is absorbing incremental Alzheimer’s optionality without near-term earnings support. Favor if the sector rotates toward quality defensives.
• For event-driven traders, sell BIIB upside calls against stock only after any post-readout bounce is exhausted; the implied move should compress once the market recognizes this is a registrational path, not a de-risked asset. Target 30-60 day tenor.
• If you want to express a constructive view, use a small-call-spread rather than outright long exposure: BIIB 6-12 month calls financed with higher strike calls. The thesis is that tau data can support valuation floor, but upside is capped until a clearer dose/efficacy narrative emerges.